2019 Annual Business Report

Our Financials & Outlook

DAVID LAWRENCE CEO of Valneva

CFO statement

“Unlocking shareholder value remains at the center of our minds.”

David Lawrence CFO of Valneva
Financials & Outlook

Our Key Figures 2019

Valneva reported strong FY 2019 financial results.

Shareholder structure (January 2020)

Shareholder structure
Our capital strategy

Our capital strategy

Valneva’s capital strategy is to leverage its commercial business for non-dilutive funding sources to complement equity capital including an intended listing on Nasdaq to co-fund the late stage development of its Lyme disease program.

Financials & Outlook

2020 Outlook

In 2020, Valneva expects to achieve major R&D milestones while increasing R&D investments in its two late-stage product candidates.

img-small

Valneva’s financial reports